345 related articles for article (PubMed ID: 20002080)
61. Pharmacotherapy for obese adolescents.
Greydanus DE; Bricker LA; Feucht C
Pediatr Clin North Am; 2011 Feb; 58(1):139-53, xi. PubMed ID: 21281853
[TBL] [Abstract][Full Text] [Related]
62. Orlistat: a review of its use in the management of patients with obesity.
Curran MP; Scott LJ
Drugs; 2004; 64(24):2845-64. PubMed ID: 15563254
[TBL] [Abstract][Full Text] [Related]
63. Development of beta 3-adrenoceptor agonists for the treatment of obesity and diabetes--an update.
Weyer C; Gautier JF; Danforth E
Diabetes Metab; 1999 Mar; 25(1):11-21. PubMed ID: 10335419
[TBL] [Abstract][Full Text] [Related]
64. The unrelenting fall of the pharmacological treatment of obesity.
Di Dalmazi G; Vicennati V; Pasquali R; Pagotto U
Endocrine; 2013 Dec; 44(3):598-609. PubMed ID: 23677499
[TBL] [Abstract][Full Text] [Related]
65. Type 2 diabetes mellitus and Invokana: an FDA approved drug.
Akhtar N
Curr Diabetes Rev; 2013 Nov; 9(6):478-90. PubMed ID: 24160357
[TBL] [Abstract][Full Text] [Related]
66. All in one: Researchers create combination drugs for diabetes and obesity.
Chakradhar S
Nat Med; 2016 Jul; 22(7):694-6. PubMed ID: 27387879
[No Abstract] [Full Text] [Related]
67. Drug interventions for the treatment of obesity in children and adolescents.
Mead E; Atkinson G; Richter B; Metzendorf MI; Baur L; Finer N; Corpeleijn E; O'Malley C; Ells LJ
Cochrane Database Syst Rev; 2016 Nov; 11(11):CD012436. PubMed ID: 27899001
[TBL] [Abstract][Full Text] [Related]
68. Guidelines for approval of anti-obesity drugs affecting atherosclerosis and/or lipids. The international union of pharmacology (IUPHAR).
Anderson JW
Am J Cardiol; 1998 Apr; 81(8A):29F-30F. PubMed ID: 9604902
[No Abstract] [Full Text] [Related]
69. The impact of pharmacotherapy on weight management in type 2 diabetes.
Hauner H
Int J Obes Relat Metab Disord; 1999 Jun; 23 Suppl 7():S12-7. PubMed ID: 10455466
[TBL] [Abstract][Full Text] [Related]
70. The effects of incretins on energy homeostasis: physiology and implications for the treatment of type 2 diabetes mellitus and obesity.
Karras S; Goulis DG; Mintziori G; Katsiki N; Tzotzas T
Curr Vasc Pharmacol; 2012 Nov; 10(6):781-91. PubMed ID: 22272906
[TBL] [Abstract][Full Text] [Related]
71. Pharmacotherapy for obesity.
Ioannides-Demos LL; Proietto J; McNeil JJ
Drugs; 2005; 65(10):1391-418. PubMed ID: 15977970
[TBL] [Abstract][Full Text] [Related]
72. Pharmacotherapy for obesity in individuals with type 2 diabetes.
Chukir T; Shukla AP; Saunders KH; Aronne LJ
Expert Opin Pharmacother; 2018 Feb; 19(3):223-231. PubMed ID: 29376439
[TBL] [Abstract][Full Text] [Related]
73. Drug treatment of obesity in the cardiovascular patient.
Charakida M; Tousoulis D; Finer N
Curr Opin Cardiol; 2013 Sep; 28(5):584-91. PubMed ID: 23928924
[TBL] [Abstract][Full Text] [Related]
74. Past, present and future of pharmacotherapy for obesity.
Benaiges D; Pedro-Botet J; Flores-Le Roux JA; Climent E; Goday A
Clin Investig Arterioscler; 2017; 29(6):256-264. PubMed ID: 28935287
[TBL] [Abstract][Full Text] [Related]
75. New therapies for diabesity.
Bailey CJ
Curr Diab Rep; 2009 Oct; 9(5):360-7. PubMed ID: 19793506
[TBL] [Abstract][Full Text] [Related]
76. Pharmacological therapies to address obesity in type 1 diabetes.
Casu A; Bilal A; Pratley RE;
Curr Opin Endocrinol Diabetes Obes; 2020 Aug; 27(4):194-206. PubMed ID: 32618631
[TBL] [Abstract][Full Text] [Related]
77. Long-term effects of weight-reducing drugs in people with hypertension.
Siebenhofer A; Jeitler K; Horvath K; Berghold A; Posch N; Meschik J; Semlitsch T
Cochrane Database Syst Rev; 2016 Mar; 3():CD007654. PubMed ID: 26934640
[TBL] [Abstract][Full Text] [Related]
78. Potential contribution of metformin to the management of cardiovascular disease risk in patients with abdominal obesity, the metabolic syndrome and type 2 diabetes.
Després JP
Diabetes Metab; 2003 Sep; 29(4 Pt 2):6S53-61. PubMed ID: 14502101
[TBL] [Abstract][Full Text] [Related]
79. Investigational drugs in Phase II clinical trials for the treatment of obesity: implications for future development of novel therapies.
Jackson VM; Price DA; Carpino PA
Expert Opin Investig Drugs; 2014 Aug; 23(8):1055-66. PubMed ID: 25000213
[TBL] [Abstract][Full Text] [Related]
80. Phentermine, topiramate and their combination for the treatment of adiposopathy ('sick fat') and metabolic disease.
Bays H
Expert Rev Cardiovasc Ther; 2010 Dec; 8(12):1777-801. PubMed ID: 20707765
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
